Header: For JP Morgan, a new White Paper: Agile Diligence in Genomics
This new white paper provides a comprehensive overview of the principles and special considerations essential for due diligence in genomics investments. We address the unique dynamics of the genomics market, highlighting both the potential and volatility of investments in this sector.
The paper delves into ten specific features of genomics due diligence, such as lab test pricing rules, Medicare valuation for algorithms and AI, and special policies unique to genomics. The white paper also explores clinical development challenges, including dealing with retrospective data and overfitting, and offers insights into defining clinical utility and understanding payer perspectives. Additionally, we discuss the implications for investors stemming from regional lab trends and the local scaling-up and -down of investment capital in the genomic testing.
White paper in the cloud HERE.
